Skip to content

    Uflex

    UFLEXMixed
    Capital Goods·18 Aug 2025
    Management Summary

    Uflex reported a resilient Q1 FY26 with revenue growth driven by strong volume increases across packaging segments, despite a slight dip in EBITDA margins. The quarter was marked by changing industry dynamics due to an accident at a large competitor, leading to better margins post-event. The company is progressing with significant CAPEX plans for Aseptic Packaging, WPP bags, and a recycling facility, which are expected to contribute substantially to revenue and EBITDA from FY27, though some projects like Asepto expansion faced delays.

    Highlights

    7
    • Revenue for Q1 FY26 stood at ₹3,922 crores, marking a 6.5% increase year-on-year.

    • Overall sales volume increased by 7.9% YoY, with packaging volumes growing 11.7% and packaging films volumes up 6.8%.

    • Liquid Packaging volumes demonstrated strong growth of 18% YoY, while Flexible Packaging volumes grew 7.4% YoY.

    • EBITDA margin for the quarter was 12%, a slight decrease from 12.7% in the same period last year.

    • PET resin production in India achieved 97% capacity utilization, and Egypt reached 75% capacity utilization.

    • The company reported no exceptional losses for foreign exchange in Q1 FY26, compared to ₹180 crores in the prior year.

    • New investments are projected to add ₹3,000 crores in additional revenues and ₹600 crores in EBITDA at 85% capacity utilization.

    What Changed2

    vs Q2 FY26

    Guidance items16 → 15 (-1)Risks discussed5 → 4 (-1)

    Key financials

    Single quarter

    04 metrics
    1. 01Revenue₹3,922 Cr+6.5%YoY
    2. 02Sales Volume Increase7.9%
    3. 03EBITDA Margin12%
    4. 04Exceptional Losses (FX)₹0 Cr

    Segment breakdown

    Packaging
    11.7% Volume Increase
    Packaging Films
    6.8% Volume Increase
    Liquid Packaging
    18% Volume Growth
    Flexible Packaging
    7.4% Volume Growth
    Holographic Films
    -5% Volume Degrowth
    PET Resin Production (India)
    97% Capacity Utilization
    PET Resin Production (Egypt)
    75% Capacity Utilization
    List

    Guidance & targets

    15
    CategoryTargetPriority
    Capacity
    Aseptic Packaging Capacity Expansion (Egypt)
    12 billion packs
    High
    Capacity
    WPP Bags Commissioning
    advanced stage
    High
    Capacity
    Recycling Facility (Noida) Commissioning
    commissioning
    High
    Capacity
    Capacity Utilization for New Investments
    85%
    Medium
    Revenue
    Additional Revenues from New Investments
    ₹3,000 crores
    Medium
    Revenue
    Revenue Growth
    10%
    Medium
    Profitability
    Additional EBITDA from New Investments
    ₹600 crores
    Medium
    Profitability
    EBITDA
    ₹2,100 crores
    Medium
    Capex
    Total Approved CAPEX
    ₹2,000 crores
    High
    Capex
    Balance CAPEX to be Spent
    ₹900 crores
    High
    Volume
    Asepto Total Volumes
    8.5-9 billion packs
    Medium
    Volume
    Film Division Total Production Volume
    132,000 tons
    Medium
    Debt
    Net Debt-to-EBITDA Peak
    4.1
    Medium
    Debt
    Net Debt-to-EBITDA Post New Projects
    under 3
    High
    Margin
    BOPP Margin over Raw Material Cost
    35%
    High

    Risks & concerns

    5
    RiskSeverity

    US Tariffs on Indian Products

    Secondary tariff of 25% on Indian products is higher than expected, impacting packaging exports from India to USA. Management expects resolution or extension.Management acknowledged

    medium

    BOPET Overcapacity and Imports

    While BOPET margins improved in India, higher imports from Southeast Asia and China are keeping prices in check. Global BOPET demand/supply balancing is expected to take at least two more years.Management acknowledged

    medium

    Asepto Expansion Delays

    The Aseptic Packaging capacity expansion (7 to 12 billion packs) has been delayed, impacting potential revenue contribution for the FY26 calendar season, with benefits now expected from FY27 onwards.Management acknowledged

    medium

    Potential for Future Overcapacity

    Management noted that if BOPP/BOPET margins increase, new players might add capacity, potentially leading to overcapacity in the next three years, as seen in the past.Management acknowledged

    low

    Areas of Evasion(1)

    • Specifics on 'low-hanging fruit' for investors

    Q&A highlights

    3

    “Asepto, we had earlier given a guidance of about 10 billion packs. So, in the Q1, we have achieved about 2.3 billion packs, which is April, May, June. So, I think we will look at somewhere between 8.5-9 billion packs now.”

    Reveals a downward revision in Asepto volume guidance for FY26 and clarifies the impact of commissioning delays on current year performance.

    asked by Chirag Singhal

    2 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Performance Overview

    Uflex reported Q1 FY26 revenues of ₹3,922 crores, a 6.5% increase year-on-year. This growth was primarily volume-driven, with overall sales volumes up 7.9%. The packaging segment saw an 11.7% volume increase, and packaging films grew by 6.8%. Despite this, the EBITDA margin for the quarter was 12%, slightly down from 12.7% in the previous year, attributed to tariff uncertainties and prior material stocking by companies. Notably, there were no exceptional foreign exchange losses this quarter, compared to ₹180 crores last year.

    02

    New Projects and Capacity Expansion

    The company is undertaking significant CAPEX, with ₹1,100 crores already spent out of an approved ₹2,000 crores, and the balance ₹900 crores to be spent by Q1 FY27. Key projects include the Aseptic Packaging greenfield expansion in Egypt (12 billion packs), WPP bags for the Pet Food industry, and a recycling facility in Noida. These new investments are projected to add ₹3,000 crores in additional revenues and ₹600 crores in EBITDA at an 85% capacity utilization, generating higher margins than conventional packaging films.

    03

    Market Dynamics and Tariffs

    The packaging film industry experienced a shift in dynamics following an accident at a large player in May, leading to reduced exports from India to Europe and lower local availability of BOPET and BOPP films. This has resulted in better margins, with full reflection expected in subsequent quarters. However, US tariffs on Indian products, particularly a 25% secondary tariff, pose a challenge, though management anticipates a resolution or extension. Exports from Mexico to the US benefit from nil duty under USMCA, providing a competitive edge.

    04

    Asepto Business Update

    The Aseptic Packaging capacity expansion, initially expected to commence in January 2025, has been delayed, with benefits now anticipated from the 2026 calendar year onwards. The FY26 volume guidance for Asepto has been revised downwards from 10 billion packs to 8.5-9 billion packs, despite Q1 achieving 2.3 billion packs. Liquid Packaging volumes still grew robustly by 18% year-on-year in Q1 FY26.

    05

    Debt and Financial Outlook

    The ongoing CAPEX has led to an increase in debt, with the net debt-to-EBITDA ratio expected to peak at around 4.1. However, management is confident that with the commissioning of new projects and the resulting revenue and profitability kick-in, the net debt-to-EBITDA ratio will come down to under 3 by FY27. The company aims for a 10% revenue growth and an EBITDA of approximately ₹2,100 crores for FY26, up from ₹1,900 crores last year.

    06

    Recycling Business and EPR Initiatives

    Uflex's upcoming recycling facility in Noida is strategically positioned to meet government guidelines requiring 30% recycled content in rigid packaging and 10% in flexible packaging. The company plans to offer a 'single pellet solution' to customers, providing a pre-mixed product with 70% virgin material and 30% recycled content, ensuring quality and ease of use. Management emphasized the long-term sustainability and formidable nature of this business segment, though patience is required for regulations to stabilize.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.